Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

Inclusion criteria

* Histologic confirmed diagnosis of malignant melanoma * Stage IV disease * Not amenable tosurgery * Measurable disease with at least one lesion whose longest diameter canbe measured as ≥ 20 mm by CT or MRI scans OR ≥ 10 mm by spiral CT * No disease that is measurable by physical examination only * No brain metastases per MRI or CT * No radiographically documented invasion of adjacent organs(duodenum, stomach, etc.) or tumor invading major blood vessels * ECOG performance status 0-1 * Life expectancy ≥ 4 months * ANC ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Hemoglobin ≥ 9 g/dL (transfusion allowed) * Creatinine ≤ 1.5 times upper limit of normal (ULN) * Total bilirubin ≤ 1.5 mg/dL (unless Gilbert syndrome) * AST ≤ 2.5 times ULN * Alkaline phosphatase ≤ 2.5 times ULN * Urine protein:creatinine ratio \< 1.0 at screening ORproteinuria \< 2+ by urine dipstick or protein ≤ 1 g by 24-hour urine collection * Negative serum pregnancy test * Not pregnant or nursing * Fertile patients must use effective contraception * Active infection requiring parenteral antibiotics * Poorly controlled high blood pressure (≥ 150 mm Hg systolic and/or100 mm Hg diastolic) despite treatment * NYHA class II-IV congestive heart failure * Serious cardiac arrhythmia requiring medication * Myocardial infarction or unstable angina within the past 6 months * Clinically significant peripheral vascular disease * Deep venous thrombosis or pulmonary embolus within the past year * Active bleeding or pathological conditions that carry high risk of bleeding (e.g., known esophageal varices) * Serious, non-healing wound (including wounds healing by secondary intention), ulcer or bone fracture * Abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within the past 6 months * History of CNS disease (e.g., primary brain tumor, vascular abnormalities, etc.) * Clinically significant stroke or TIA within the past 6 months * Seizures not controlled with standardmedical therapy * Peripheral neuropathy ≥ grade 2 * History of other malignancy within the past 5 years except basal cell or squamous cell carcinoma of the skin treatable with local resection only or carcinoma in situ of the cervix * Significant traumatic injury within the past 4 weeks * History of hypertensive crisis or hypertensive encephalopathy * Active or recent (≤ 30 days) history of hemoptysis (≥ ½ teaspoon of bright red blood per episode) * Known hypersensitivity to any of the components of bevacizumab * Known to be HIV positive * Current or known history of hepatitis * Prior adjuvant chemotherapy and/or immunotherapy for this cancer allowed * No prior treatment with agents disrupting VEGF activity (i.e., bevacizumab,VEGF-trap, anti-VEGFR Mab) * No ongoing need for full-dose oral or parenteral anticoagulation * No ongoing anti-platelet treatment other than low-dose aspirin(i.e., aspirin 81 mg daily) * No other investigational agents within the past 4 weeks * No major surgical procedure or open biopsy within the past 4 weeks * No fine needle aspirations or core biopsies within the past 7 days * No prior chemotherapy in the metastatic setting * No prior treatment with sunitinib malate or sorafenib * No prior treatment with any taxane-based chemotherapy * Patients who have had \> 25% of their functional bone marrow irradiated are not eligible for this trial * No adjuvant radiation therapy within the past 4 weeks * More than 2 weeks since prior and no concurrent palliative radiation therapy * No concurrent major surgical procedure * No concurrent participation in another clinical study for procedures or agents that treat the same primary study malignancy